

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



ORGANON

Ezetimibe / Simvastatin Formulation

Version 7.1 Revision Date: 09/30/2023 SDS Number: 28137-00022 Date of last issue: 04/04/2023
Date of first issue: 11/04/2014

SECTION 1. IDENTIFICATION

Product name : Ezetimibe / Simvastatin Formulation

Manufacturer or supplier's details

Company name of supplier : Organon & Co.
Address : 30 Hudson Street, 33nd floor
Jersey City, New Jersey, U.S.A 07302
Telephone : 1-551-430-6000
Emergency telephone : 1-215-631-6999
E-mail address : EHSSTEWART@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Combustible dust

Skin irritation : Category 2

Skin sensitization : Category 1

Specific target organ toxicity : Category 1 (Liver, muscle, optic nerve, Eye)
- repeated exposure

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.
H315 Causes skin irritation.
H317 May cause an allergic skin reaction.
H372 Causes damage to organs (Liver, muscle, optic nerve, Eye) through prolonged or repeated exposure.

Precautionary Statements : **Prevention:**
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P272 Contaminated work clothing must not be allowed out of

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version 7.1 Revision Date: 09/30/2023 SDS Number: 28137-00022 Date of last issue: 04/04/2023
Date of first issue: 11/04/2014

the workplace.
P280 Wear protective gloves.

Response:

P302 + P352 IF ON SKIN: Wash with plenty of soap and water.
P314 Get medical attention if you feel unwell.
P333 + P313 If skin irritation or rash occurs: Get medical attention.
P362 + P364 Take off contaminated clothing and wash it before reuse.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 10 - < 20
Ezetimibe	163222-33-1	>= 10 - < 20
Simvastatin	79902-63-9	>= 10 - < 20
Magnesium stearate	557-04-0	>= 1 - < 5

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.
- In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Causes skin irritation.
May cause an allergic skin reaction.
Causes damage to organs through prolonged or repeated

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
7.1	09/30/2023	28137-00022	Date of first issue: 11/04/2014

exposure.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Fluorine compounds
Metal oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
7.1	09/30/2023	28137-00022	Date of first issue: 11/04/2014

disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- | | | |
|-----------------------------|---|--|
| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : | Use only with adequate ventilation. |
| Advice on safe handling | : | Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment. |
| Conditions for safe storage | : | Keep in properly labeled containers.
Store in accordance with the particular national regulations. |
| Materials to avoid | : | Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases |

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

- | | |
|------------------------|---|
| inert or nuisance dust | 50 Million particles per cubic foot
Value type (Form of exposure): TWA (total dust)
Basis: OSHA Z-3 |
| | 15 mg/m ³
Value type (Form of exposure): TWA (total dust)
Basis: OSHA Z-3 |
| | 5 mg/m ³
Value type (Form of exposure): TWA (respirable fraction)
Basis: OSHA Z-3 |

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version 7.1 Revision Date: 09/30/2023 SDS Number: 28137-00022 Date of last issue: 04/04/2023
Date of first issue: 11/04/2014

15 Million particles per cubic foot
Value type (Form of exposure): TWA (respirable fraction)
Basis: OSHA Z-3

Dust, nuisance dust and particulates 10 mg/m³
Value type (Form of exposure): PEL (Total dust)
Basis: CAL PEL

5 mg/m³
Value type (Form of exposure): PEL (respirable dust fraction)
Basis: CAL PEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m ³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m ³	OSHA Z-1
Ezetimibe	163222-33-1	TWA	25 µg/m ³ (OEB 3)	Internal
		Wipe limit	250 µg/100 cm ²	Internal
Simvastatin	79902-63-9	TWA	25 µg/m ³ (OEB 3)	Internal
	Further information: DSEN			
		Wipe limit	250 µg/100 cm ²	Internal
Magnesium stearate	557-04-0	TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
7.1	09/30/2023	28137-00022	Date of first issue: 11/04/2014

by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



ORGANON

Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
7.1	09/30/2023	28137-00022	Date of first issue: 11/04/2014

Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
7.1	09/30/2023	28137-00022	Date of first issue: 11/04/2014

Incompatible materials	:	Avoid dust formation.
Hazardous decomposition products	:	Oxidizing agents
	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

Cellulose:

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg

Ezetimibe:

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
		LD50 (Mouse): > 5,000 mg/kg
		LD50 (Dog): > 3,000 mg/kg
Acute inhalation toxicity	:	Remarks: No data available
Acute dermal toxicity	:	Remarks: No data available
Acute toxicity (other routes of administration)	:	LD50 (Rat): > 2,000 mg/kg Application Route: Intraperitoneal
		LD50 (Mouse): > 1,000 - < 2,000 mg/kg Application Route: Intraperitoneal

Simvastatin:

Acute oral toxicity	:	LD50 (Rat): 5,000 mg/kg
		LD50 (Mouse): 3,800 mg/kg

Magnesium stearate:

Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 423
---------------------	---	--

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
7.1	09/30/2023	28137-00022	Date of first issue: 11/04/2014

Assessment: The substance or mixture has no acute oral toxicity

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation

Causes skin irritation.

Components:

Ezetimibe:

Species : Rabbit
Result : No skin irritation

Simvastatin:

Species : Rabbit
Remarks : Moderate skin irritation

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Ezetimibe:

Species : Rabbit
Result : No eye irritation

Simvastatin:

Species : Rabbit
Remarks : slight irritation

Magnesium stearate:

Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Respiratory or skin sensitization

Skin sensitization

May cause an allergic skin reaction.

Respiratory sensitization

Not classified based on available information.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version 7.1 Revision Date: 09/30/2023 SDS Number: 28137-00022 Date of last issue: 04/04/2023
Date of first issue: 11/04/2014

Components:

Ezetimibe:

Test Type : Maximization Test
Species : Guinea pig
Result : negative

Simvastatin:

Assessment : Probability or evidence of skin sensitization in humans
Result : positive

Magnesium stearate:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406
Result : negative
Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Ezetimibe:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Metabolic activation: with and without metabolic activation
Result: negative

Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version 7.1 Revision Date: 09/30/2023 SDS Number: 28137-00022 Date of last issue: 04/04/2023
Date of first issue: 11/04/2014

Simvastatin:

- Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
- Test Type: Alkaline elution assay
Result: negative
- Test Type: Chromosomal aberration
Result: negative
- Test Type: In vitro mammalian cell gene mutation test
Result: negative
- Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative
- Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Magnesium stearate:

- Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials
- Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials
- Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:

Cellulose:

- Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Ezetimibe:

- Species : Rat, female
Application Route : oral (feed)
Exposure time : 104 weeks

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version 7.1 Revision Date: 09/30/2023 SDS Number: 28137-00022 Date of last issue: 04/04/2023
Date of first issue: 11/04/2014

Result : negative

Species : Rat, male
Application Route : oral (feed)
Exposure time : 104 weeks
Result : negative

Species : Mouse
Application Route : oral (feed)
Exposure time : 104 weeks
Result : negative

Simvastatin:

Species : Mouse
Application Route : Oral
Exposure time : < 92 weeks
Target Organs : Harderian gland
Tumor Type : Liver, Lungs
Remarks : The significance of these findings for humans is not certain.

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Tumor Type : Liver, Thyroid
Remarks : The significance of these findings for humans is not certain.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Ezetimibe:

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
7.1	09/30/2023	28137-00022	Date of first issue: 11/04/2014

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, male and female
Fertility: NOAEL: > 1,000 mg/kg body weight
Result: No effects on fertility., No fetotoxicity.

Effects on fetal development : Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight
Result: No adverse effects.

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight
Result: No adverse effects.

Simvastatin:

Effects on fertility : Test Type: Fertility
Species: Rat, male
Application Route: Oral
Fertility: LOAEL: 25 mg/kg body weight

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Embryo-fetal toxicity.: NOAEL: 25 mg/kg body weight
Result: No teratogenic effects., No adverse effects.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Embryo-fetal toxicity.: NOAEL: 10 mg/kg body weight
Result: No teratogenic effects., No adverse effects.

Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Embryo-fetal toxicity.: LOAEL: 60 mg/kg body weight
Result: Teratogenic potential.
Remarks: Based on data from similar materials

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
7.1	09/30/2023	28137-00022	Date of first issue: 11/04/2014

Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Liver, muscle, optic nerve, Eye) through prolonged or repeated exposure.

Components:

Simvastatin:

Target Organs : Liver, muscle, optic nerve, Eye
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Cellulose:

Species : Rat
NOAEL : $\geq 9,000$ mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Ezetimibe:

Species : Dog
NOAEL : 1,000 mg/kg
Application Route : Oral
Exposure time : 90 d
Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 1,500 mg/kg
Application Route : Oral
Exposure time : 90 d
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 90 d
Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 300 mg/kg
Application Route : Oral
Exposure time : 1 y
Remarks : No significant adverse effects were reported

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version 7.1 Revision Date: 09/30/2023 SDS Number: 28137-00022 Date of last issue: 04/04/2023
Date of first issue: 11/04/2014

Simvastatin:

Species : Rat
NOAEL : 5 mg/kg
LOAEL : 30 mg/kg
Application Route : Oral
Exposure time : 14 - 104 Weeks
Target Organs : Liver, Testis, Musculo-skeletal system, Eye

Species : Dog
LOAEL : 10 mg/kg
Application Route : Oral
Exposure time : 14 - 104 Weeks
Target Organs : Liver, Testis, Eye

Species : Rabbit
NOAEL : 30 mg/kg
LOAEL : 50 mg/kg
Application Route : Oral
Target Organs : Liver, Kidney

Magnesium stearate:

Species : Rat
NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Components:

Ezetimibe:

Not applicable

Experience with human exposure

Components:

Ezetimibe:

Ingestion : Symptoms: Headache, Nausea, Vomiting, Diarrhea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain

Simvastatin:

Skin contact : Remarks: May produce an allergic reaction.
Ingestion : Target Organs: Liver
Symptoms: upper respiratory tract infection, Headache, Abdominal pain, constipation, Nausea
Target Organs: Musculo-skeletal system

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



ORGANON

Ezetimibe / Simvastatin Formulation

Version 7.1 Revision Date: 09/30/2023 SDS Number: 28137-00022 Date of last issue: 04/04/2023
Date of first issue: 11/04/2014

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Ezetimibe:

Toxicity to fish : LC50 (*Pimephales promelas* (fathead minnow)): > 0.125 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): > 4 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EC50 (*Pseudokirchneriella subcapitata* (green algae)): > 0.317 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

NOEC (*Pseudokirchneriella subcapitata* (green algae)): 0.317 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (*Pimephales promelas* (fathead minnow)): 0.051 mg/l
Exposure time: 33 d
Method: OECD Test Guideline 210

NOEC (*Cyprinodon variegatus* (sheepshead minnow)): 4 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (*Daphnia magna* (Water flea)): 0.282 mg/l
Exposure time: 21 d
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 4.4 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.

NOEC: 4.4 mg/l

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
7.1	09/30/2023	28137-00022	Date of first issue: 11/04/2014

Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.

Simvastatin:

- Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 2.91 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 3.5 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 25 mg/l
Exposure time: 96 h
- NOEC (Pseudokirchneriella subcapitata (green algae)): 25 mg/l
Exposure time: 96 h
- Toxicity to microorganisms : EC50: > 30 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
- NOEC: 21 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Magnesium stearate:

- Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials
- Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Method: Directive 67/548/EEC, Annex V, C.2.
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.
- Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
7.1	09/30/2023	28137-00022	Date of first issue: 11/04/2014

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Ezetimibe:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 6.8 %
Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(4.5 d)
Method: OECD Test Guideline 111

Simvastatin:

Biodegradability : Result: rapidly degradable

Stability in water : Hydrolysis: 50 %(3.2 d)

Magnesium stearate:

Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Ezetimibe:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 173
Exposure time: 97 d
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.36

Simvastatin:

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
7.1	09/30/2023	28137-00022	Date of first issue: 11/04/2014

Partition coefficient: n-octanol/water : log Pow: > 4.07

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

Components:

Ezetimibe:

Distribution among environmental compartments : log Koc: 4.35
Method: OECD Test Guideline 106

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Ezetimibe, Simvastatin)

Class : 9

Packing group : III

Labels : 9

Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3077

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.
(Ezetimibe, Simvastatin)

Class : 9

Packing group : III

Labels : Miscellaneous

Packing instruction (cargo aircraft) : 956

Packing instruction (passenger aircraft) : 956

Environmentally hazardous : yes

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
7.1	09/30/2023	28137-00022	Date of first issue: 11/04/2014

IMDG-Code

UN number	: UN 3077
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Simvastatin)
Class	: 9
Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F
Marine pollutant	: yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

UN/ID/NA number	: UN 3077
Proper shipping name	: Environmentally hazardous substance, solid, n.o.s. (Ezetimibe, Simvastatin)
Class	: 9
Packing group	: III
Labels	: CLASS 9
ERG Code	: 171
Marine pollutant	: yes(Ezetimibe, Simvastatin)
Remarks	: Above applies only to containers over 119 gallons or 450 liters. Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards	: Combustible dust Respiratory or skin sensitization Specific target organ toxicity (single or repeated exposure) Skin corrosion or irritation
-----------------------------	---

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
7.1	09/30/2023	28137-00022	Date of first issue: 11/04/2014

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

D-Glucose, 4-O-β-D-galactopyranosyl-, monohydrate	64044-51-5
Cellulose	9004-34-6
Ezetimibe	163222-33-1
Simvastatin	79902-63-9
Croscarmellose sodium	74811-65-7

California Prop. 65

WARNING: This product can expose you to chemicals including tert-Butyl-4-methoxyphenol, which is/are known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.

California Permissible Exposure Limits for Chemical Contaminants

Cellulose	9004-34-6
Magnesium stearate	557-04-0

The ingredients of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

SECTION 16. OTHER INFORMATION

Further information

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



ORGANON

Ezetimibe / Simvastatin Formulation


Version
7.1

Revision Date:
09/30/2023

SDS Number:
28137-00022

Date of last issue: 04/04/2023
Date of first issue: 11/04/2014

NFPA 704:



HMIS® IV:

HEALTH	*	3
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
CAL PEL	:	California permissible exposure limits for chemical contaminants (Title 8, Article 107)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
OSHA Z-3	:	USA. Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts
ACGIH / TWA	:	8-hour, time-weighted average
CAL PEL / PEL	:	Permissible exposure limit
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA	:	8-hour time weighted average
OSHA Z-3 / TWA	:	8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Pre-

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



ORGANON

Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
7.1	09/30/2023	28137-00022	Date of first issue: 11/04/2014

vention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 09/30/2023

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8